Bispecific antibodies (bsAbs) represent a rapidly advancing class of therapeutic biologics engineered to simultaneously bind two distinct antigens or epitopes. Their dual-targeting capability enables novel mechanisms of action, including redirected cytotoxicity, receptor clustering, and enhanced specificity, which are being exploited across oncology, immunology, and infectious disease applications. As of 2026, the clinical and commercial landscape for bispecifics is expanding, with multiple candidates progressing through late-stage trials and gaining regulatory attention.
Mim8 (denecimig) is an investigational bispecific monoclonal antibody developed by Novo Nordisk for prophylactic treatment of hemophilia A. It functions as a Factor VIIIa (FVIIIa) mimetic by simultaneously binding Factor IXa and Factor X, facilitating their interaction and restoring thrombin generation in the absence of functional FVIII. This mechanism is designed to reduce the frequency of bleeding episodes in patients with congenital FVIII deficiency, including those with inhibitors.
Denecimig is administered subcutaneously and offers dosing flexibility with regimens of once weekly, every two weeks, or once monthly. This approach allows personalized prophylaxis and may improve adherence through reduced treatment burden. The BLA for Mim8 was submitted to the FDA in September 2025, supported by data from the FRONTIER clinical program. These trials evaluated safety and efficacy across age groups, disease severity, and inhibitor status. If approved, Mim8 will be the first FVIIIa mimetic available in a single-use, prefilled pen with multiple dosing options for both pediatric and adult patients with hemophilia A.
Anbenitamab (KN026) is a bispecific antibody that targets two non-overlapping epitopes on the HER2 receptor, enabling comprehensive signal blockade. The molecule maintains Fc effector function and exhibits improved tumor inhibition compared to trastuzumab and pertuzumab, including activity in trastuzumab-resistant models.
Anbenitamab has demonstrated antitumor efficacy in HER2-positive breast and gastric cancers. In the pivotal Phase II/III trial KN026-001, KN026 combined with chemotherapy showed significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard care in patients with HER2-positive gastric or gastroesophageal junction cancer who failed prior trastuzumab-based therapy. No new safety signals were reported, and cardiotoxicity and immunogenicity remained low. Earlier Phase II results presented at ESMO 2024 reported an ORR of 40.0% and median PFS of 8.6 months.
On September 12, 2025, the National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for KN026 as a Class 1 therapeutic biologic. It has also received Breakthrough Therapy Designation (November 2023) and Priority Review status (August 2025). KN026 may become the first approved bispecific HER2 therapy for second-line gastric cancer in China.
Silevimig is a recombinant, fully human bispecific antibody developed for passive immunization against rabies virus (RABV). It targets epitopes I and/or III on the RABV glycoprotein, blocking viral entry into neural tissue by preventing interaction with host receptors. This mechanism offers immediate protection during the high-risk window before vaccine-induced immunity develops.
Silevimig mimics a monoclonal antibody cocktail within a single molecule to ensure broad neutralization across viral strains. In a Phase III trial, Silevimig demonstrated non-inferior efficacy to human rabies immunoglobulin (HRIG), without impairing vaccine response. The study supports its use in adults with Category III rabies exposure, who require both passive and active immunization.
On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was accepted by the NMPA.
Izalontamab brengitecan (iza-bren) is an EGFRxHER3-targeting bispecific antibody-drug conjugate (ADC) for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Iza-bren targets both EGFR and HER3, two receptors frequently co-expressed in epithelial malignancies, and delivers a topoisomerase I inhibitor payload to induce DNA damage and apoptosis upon internalization.
The antibody component of iza-bren simultaneously binds EGFR and HER3, blocking proliferative signaling and promoting internalization of the ADC complex. Once internalized, the cytotoxic payload is released, leading to genotoxic stress and tumor cell death. This dual-targeting mechanism addresses oncogenic bypass and resistance pathways commonly observed following tyrosine kinase inhibitor (TKI) therapy.
Breakthrough Therapy Designation (BTD) was granted by the U.S. FDA on August 18, 2025, for patients with locally advanced or metastatic EGFR-mutant NSCLC who have progressed after EGFR TKI and platinum-based chemotherapy.
Petosemtamab (MCLA-158) is a bispecific full-length IgG1 antibody designed to target EGFR and LGR5. It employs a three-pronged mechanism of action: inhibition of EGFR signaling, LGR5-mediated internalization and degradation of EGFR, and enhancement of antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) through its low-fucose Fc region. This multifaceted approach aims to suppress oncogenic signaling and promote immune-mediated tumor cell clearance in EGFR-expressing epithelial cancers.
On February 18, 2025, the U.S. FDA granted Breakthrough Therapy Designation (BTD) for petosemtamab in combination with pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC) in PD-L1 positive patients (CPS ≥1). It previously received BTD and Fast Track designation for use in later-line r/m HNSCC following progression on platinum-based chemotherapy and anti-PD-1 therapy.
Tovecimig (CTX-009) is a bispecific antibody targeting both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), two critical regulators of tumor angiogenesis and vascular development. Tovecimig is designed to inhibit both Notch and VEGF signaling pathways, which contribute to tumor progression, immune suppression, and resistance to standard anti-angiogenic therapies.
On April 1, 2025, tovecimig (CTX-009) met its primary endpoint in the ongoing randomized phase 2/3 study in patients with biliary tract cancer. Tovecimig represents a novel therapeutic strategy for BTC patients without actionable mutations, a group that currently lacks approved second-line options. Standard off-label therapies in this setting yield ORRs of ~5%, and median overall survival remains around six months.
January 2026 deal activity leaned heavily toward bispecific, trispecific, and AD……
This article examines HEK293 and CHO across biological characteristics, producti……
ADCs to watch in 2026. Clinical Trials, Primary Endpoints.
PepTalk 2026 highlights and event recap. Biotech antibody conference!
ScientistとScience Exchangeとのご利用可能です。
